Friday , 17 August 2018

Home » RESOURCES » INVESTING » Arena Pharmaceuticals stock soars after weight drug approved in Mexico

Arena Pharmaceuticals stock soars after weight drug approved in Mexico

Shares of Arena Pharmaceuticals Inc. surged 8.8% in premarket trade Thursday, after the company said its weight management drug was granted approval for commercialization in Mexico by Eisai Laboratories. Arena will receive a $1 million milestone payment as a result of the approval. The U.S. brand name for Arena’s weight management drug is Belviq. The product is expected to be available later this year. “Currently more than 70% of the Mexican population is either overweight or obese,” said Eisai Chief Operating Officer Shaji Procida. “Without intervention, these numbers are projected to increase.” Arena’s stock had tumbled 16% year to date through Wednesday, while the S&P 500 has gained 5.3%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Arena Pharmaceuticals stock soars after weight drug approved in Mexico Reviewed by on . Shares of Arena Pharmaceuticals Inc. surged 8.8% in premarket trade Thursday, after the company said its weight management drug was granted approval for commerc Shares of Arena Pharmaceuticals Inc. surged 8.8% in premarket trade Thursday, after the company said its weight management drug was granted approval for commerc Rating:
scroll to top